Skip to main content
Premium Trial:

Request an Annual Quote

Immunovia, JW BioScience Ink Licensing Agreement for Early Pancreatic Cancer Detection Biomarkers

NEW YORK ─ Immunovia said on Monday that it has signed a global licensing agreement with South Korea-based JW BioScience that gives Immunovia the intellectual property rights for two biomarkers for the early detection of pancreatic cancer.

The Lund, Sweden-based diagnostic company said it had discovered the biomarkers independently of JW BioScience, but they are also part of JW BioScience's intellectual property portfolio. Immunovia said it has now secured intellectual property rights to the biomarkers, which are part of the diagnostic signature for its Immray PanCan-d blood test for the early detection of pancreatic cancer.

Financial and other terms of the licensing agreement were not disclosed.

"By entering into this agreement, Immunovia and JW BioScience will also evaluate possibilities for commercial collaboration to enable early detection of pancreatic cancer in the Korean market," Immunovia CEO Patrik Dahlen said in a statement.

In August, the firm announced it had received final approval to begin patient testing for its Immray PanCan-d blood test in the US through its laboratory in Marlborough, Massachusetts.